Poorva Bindal, MD

Lymphoma, Myeloma and Cell-based therapies @UMassChan | Former Fellow @BIDMCHealth @harvardmed | @UConnIM alum | 🇮🇳 🇺🇸

[Department of Medicine @UMass_Medicine]

This month, we are excited to feature @PoorvaBindal , MD, as our Chair's Spotlight feature! Learn more about Dr. Bindal and her work by reading the full spotlight on our website!

https://t.co/aI414tFt6w

[Corey Cutler @DrCCutler]

Tomorrow, I will start a 2-day, 160 mile @PanMass challenge bike ride to support innovative cancer research at @DanaFarber .
Want to support my ride? Donate here:
https://t.co/Q5Vm3XNHFl
Thanks!

[Krishna Komanduri, MD, FASTCT @drkomanduri]

Exhausted but filled with gratitude after the @ASTCT Clinical Research Training Course.

A week spent with some of the most talented faculty in the field of #celltherapy and a gifted class of scholars who will replace us and advance our field.

What a special community! 🙏🏽🥰🩺

[Portia Smallbone @PortiaSmallbone]

What an epic week at @ASTCT Clinical Research Training Course. Leaving Utah feeling inspired and encouraged, with new mentors and great friends. Thank you so much to the organizers & faculty for truly one of the best professional experiences. #CRTC2024

[Manni Mohyuddin @ManniMD1]

Finally an analysis of SLiM MM versus traditional CRAB MM.

Glad to see this. Was disappointing that the obvious lead-time bias was not pointed out, and instead the obviously better outcomes for SLiM MM (due to earlier detection/indolent biology) was used to make an argument for treating SLiM MM.

When we see such results, IMO, rather than delve into a basic science explanation (clonal evolution etc etc etc), we should start by calling it what it is: lead-time bias.

https://t.co/KcItheDV6x

Given how poorly the SLiM MM criteria have aged (2 year progression risk to CRAB MM actually 30%, rather than 80% which is what it was thought to be in 2014), this paper further reinforces that such patients should not be treated.

(Also inclusion of such patients in MM newly diagnosed clinical trials will lead to improved outcomes compared to earlier trials, even if other treatments the same. Perhaps thats contributing to excellent outcomes of IMROZ VRd control arm)

#mmsm
@AaronGoodman33

[Manni Mohyuddin @ManniMD1]

The FDA just approved cilta-cel for early relapse in myeloma (1 prior line of therapy, including PI and IMiD, and refractory to lenalidomide).

My thoughts on the approval of cilta-cel for early relapse in myeloma.

An educational thread:

#mmsm

1/

[Manni Mohyuddin @ManniMD1]

Belantamab/bortezomib/dexa (BVd) had a much better PFS than dara/bortezomib/dex (DVd) in a Phase 3 trial.

What are we to make of this result?

Lets analyze this in detail!

An educational thread on appraisal, and my thoughts on how this may affect my practice/thinking.

#mmsm

[Manni Mohyuddin @ManniMD1]

The difference in refractoriness to last line of therapy is a very important aspect when we look at performance of regimens in trials and compare trials.

@PoorvaBindal wrote a paper about how this varies across trials, and isnt always reported.

https://t.co/E28L3O5BoA

[Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1]

Does a "mass effect" prevent optimal results with CARTs and bispecific antibodies (BsAb) in MM?

1) I suspect so, and we need to study this in detail to improve patient outcomes.

2) Until then, I think a reasonable case can be made for using local radiation therapy in some cases with large masses not controlled by prior or bridging treatment (stay until the end).

Why?

#mmSM
1/x

[Abdul Muqtadir Abbasi @AbbasiMuqtadir]

You prescribed iv iron to patient in iron deficiency anemia and 3 days later patient comes up with severe fatigue? Medicine residents!!!!

Very very important to know.

[Poorva Bindal, MD @PoorvaBindal]

@DrNikitaMehra @bagalbp @TataMemorial @atharvak03 @iitbombay @ActImmuno @ACTREC_TMC Congratulations to all! Great representation from India. Proud moment 👏🏼👏🏼👏🏼

[Poorva Bindal, MD @PoorvaBindal]

@SurbhiSidanaMD @NBahlis It was a phenomenal session! Thank you for taking the time.

[Tarsheen Sethi, MD, MSCI @tarsheen2]

Lovely to meet all these amazing @HemOncWomenDocs at #ASH23 @PoorvaBindal @PallawiTorkaMD @nadahamad @SSundaramMD

[calliecoombs @calliecoombsmd]

Updated follow up from CLL cohort of BRUIN trial - high ORR though pts with prior BCL2i with a bit shorter PFS than BCL2i naive pts #ASH23

[Raul Cordoba, MD, PhD @DrRaulCordoba]

N-AVD vs BV-AVD in older patients with #Hodgkin #lymphoma. No words needed. To me, the new SoC #lymsm #ASH23

[Poorva Bindal, MD @PoorvaBindal]

@DrFredLocke addressed the #FDA probe into “serious” risk of T cell malignancy after CAR T #ASH2023
The math is simple:
✅ 0.12% risk of TCL after Dx of B cell lymphoma
✅ 0.15% risk of TCL after CAR T
‼️8.6%‼️ risk of death if randomised to chemo/transplant instead of CAR T!

[Manni Mohyuddin @ManniMD1]

The majority of those who responded chose bortezomib as a safer option relative to carfilzomib.

Some thoughts in this brief 🧵 below.

There is a head to head trial comparing bortezomib to carfilzomib in transplant ineligible patients

https://t.co/JGkRdSoU81

Median age=72

[Poorva Bindal, MD @PoorvaBindal]

Tips for Success As an Academic Clinical Investigator | Fantastic read with practice, actionable tips! Thank you ⁦@StephanieLeeMD⁩ 👏🏼 https://t.co/xlnQw92y91

[Deepa Rangachari, MD, FASCO @DeepaRangachari]

Congrats to BIDMC fellowship alums @rushadpatell and @PoorvaBindal for their innovative work! Delighted to discuss our novel curriculum re medical cannabis in cancer patients at #ASCO23. @BIDMC_HOFellows @BIDMC_Medicine

[Nature Medicine @NatureMedicine]

Prophylactic use of anakinra, an IL-1 receptor inhibitor, reduced severe #neurotoxicity incidence in patients with r/r #lymphoma treated with anti-CD19 #CARTcells #immunotherapy @jaeparkmd @karthik_nath17 @Michel_Sadelain @MSKCancerCenter @MSK_DeptOfMed

https://t.co/eE9Chc0xgO